Mirum Pharmaceuticals (NASDAQ:MIRM) Research Coverage Started at Royal Bank Of Canada

Royal Bank Of Canada assumed coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report report published on Tuesday morning, Marketbeat reports. The brokerage issued an outperform rating and a $130.00 target price on the stock.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Citizens Jmp raised their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, December 19th. Morgan Stanley increased their price objective on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Finally, Robert W. Baird upped their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.17.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $105.49 on Tuesday. The business’s 50-day moving average is $89.43 and its two-hundred day moving average is $77.22. The company has a market capitalization of $5.42 billion, a P/E ratio of -122.66 and a beta of 0.49. Mirum Pharmaceuticals has a fifty-two week low of $36.88 and a fifty-two week high of $107.41. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 968 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the transaction, the senior vice president owned 4,503 shares of the company’s stock, valued at approximately $465,159.90. This trade represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Patrick J. Heron bought 131,425 shares of the stock in a transaction dated Friday, January 23rd. The shares were acquired at an average price of $68.48 per share, for a total transaction of $8,999,984.00. Following the completion of the transaction, the director owned 459,010 shares of the company’s stock, valued at approximately $31,433,004.80. The trade was a 40.12% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 45,136 shares of company stock valued at $4,352,029 over the last quarter. 14.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Emerald Advisers LLC grew its holdings in Mirum Pharmaceuticals by 20.9% in the third quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock valued at $27,095,000 after purchasing an additional 63,834 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Mirum Pharmaceuticals in the third quarter valued at $808,000. Candriam S.C.A. grew its position in Mirum Pharmaceuticals by 8.0% during the third quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after acquiring an additional 30,021 shares during the period. Baader Bank Aktiengesellschaft purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at about $503,000. Finally, TimesSquare Capital Management LLC acquired a new stake in Mirum Pharmaceuticals during the third quarter worth about $22,041,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.